Olga Babaev

Olga received Dr.rer.nat (summa cum laude) from Göttingen University in Germany and a B.Pharm (summa cum laude) from Ben-Gurion University in Israel. Prior to joining Boehringer Ingelheim Pharma, Olga worked as a Post-Doctoral Researcher at the Max Planck Institute for Experimental Medicine in Göttingen. During this time, she led several multidisciplinary projects to discover novel therapeutic targets for anxiety treatment and established an in-vivo lab in her department. Additionally, Olga wrote four papers, successfully secured two grants, and led a Public Relations team for two international conferences. 

Olga then moved to Boehringer Ingelheim Pharma in Biberach, Germany, and became a Post-Doctoral Researcher in the Department of CNS Diseases Research. During this time, she established novel paradigms to evaluate pre-clinical models of depression and proposed two novel therapeutic concepts for the treatment of motivation-related deficits in depression and schizophrenia. In this role, Olga supported the CNS research portfolio and initiated external collaborations. After 12 years in research, Olga started a new role as a Medical Writer in Clinical Development at Boehringer Ingelheim. She now works with biostatisticians, physicians, patent attorneys, clinical trial leaders, and research scientists to organize the preparation and submission of clinical documents required for the approval of new drugs for the treatment of cardiometabolic disorders.